news
European manufacturing facility to strengthen gene therapy supply
The new manufacturing facility in Finland will aid global supply of the first FDA-approved intravesical non-replicating gene therapy for adults with a common cancer.
List view / Grid view
Ferring Pharmaceuticals
news
Ferring reveals long-term data for cancer gene therapy
New data from a Phase III gene therapy trial has demonstrated a 90 percent three-year overall survival rate for its participants with a high-risk bladder cancer.
news
Safety analysis published for C. diff biotherapeutic
The largest safety evaluation of any microbiota-based live biotherapeutic includes data for up to two years for the first approved microbiome-based treatment for recurrent Clostridioides difficile (C. diff).
news
Bioavailability enhancement services market to exhibit 11 percent CAGR
Between 2022 and 2035, the bioavailability enhancement services market will see an 11 percent compound annual growth rate, a report has predicted.
news
First faecal microbiota product approved for C. diff
The first faecal microbiota product to prevent recurrence of Clostridioides difficile infection in adults has been approved by the FDA.
article
Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases
The human gut contains the largest ecosystem of microbial species having complex host-microbiome interactive networks that contribute to our physiology and regulate our immune system. An imbalance in this host-microbiome interaction is associated with disease and the ability to restore or stabilise the network by introducing a rich and diverse…
news
UK MHRA announces two Class 2 medicine recalls
A batch of Nitrofurantoin and all unexpired stock of Desmopressin nasal spray are being recalled in the UK, the MHRA has announced.
news
Female infertility drug market to exhibit CAGR of 3.4 percent
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
article
Personalised medicine and partnering – key areas for Ferring
Michel Pettigrew, President of the Executive Board and Chief Operating Officer at Ferring Pharmaceuticals, explains how his company’s decentralised model and focus on entrepreneurialism is helping it to deliver personalised medicine.
article
21st Anniversary Supplement
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
news
Ferring receives positive CHMP opinion for IVF aid Rekovelle
19 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Non-inferiority was demonstrated in a Phase 3 trial for the co-primary endpoints of ongoing pregnancy rate and ongoing implantation rate for Rekovelle...
news
Ferring announces data from its Phase III ESTHER trials
4 July 2016 | By Victoria White, Digital Content Producer
ESTHER-1 assessed an individualised dosing regimen of follitropin delta compared to follitropin alfa in women undergoing their first cycle of IVF...
news
NICE says ‘yes’ to degarelix for men with prostate cancer and spinal metastases
1 July 2016 | By Victoria White, Digital Content Producer
NICE has recommended Ferring’s Firmagon (degarelix) for men with advanced-hormone dependent prostate cancer and spinal metastases...
news
Trial of selepressin for treatment of septic shock begins
17 August 2015 | By Victoria White
Ferring Pharmaceuticals has started patient enrollment in a Phase 2b/3 clinical trial of selepressin for the treatment of septic shock...
